The National Institute for Health and Care Excellence (NICE) has published its positive guidance for the first selective interleukin (IL)-23 inhibitor to treat moderate to severe plaque psoriasis.
Original Article: NICE publishes positive guidance for Tremfya for plaque psoriasis